Efficacy and Tolerability of a Fixed Combination of Perindopril/Amlodipine/Indapamide in Patients with Essential Hypertension: Pilot Study / Efikasnost I Tolerabilnost Fiksne Kombinacije Perindopril/Amlodipin/Indapimida Kod Pacijenata Sa Esencijalnom Hipertenzijom: Pilot Studija
Hypertension is the major risk factor in Serbia and worldwide for the morbidity and mortality from cardiovascular and cerebrovascular diseases. A majority of patients need two or more antihypertensive drugs to adequately control blood pressure. Our study group consisted of 12 patients with uncontrol...
Saved in:
Published in | Serbian journal of experimental and clinical research Vol. 17; no. 1; pp. 21 - 26 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
De Gruyter Open
01.03.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Hypertension is the major risk factor in Serbia and worldwide for the morbidity and mortality from cardiovascular and cerebrovascular diseases. A majority of patients need two or more antihypertensive drugs to adequately control blood pressure.
Our study group consisted of 12 patients with uncontrolled essential hypertension, without comorbidities, divided in two groups and followed for 12 weeks. The first group was treated with a single-pill of fixed-combination Perindopril 5 mg/Indapamide 1.25 mg and an additional tablet of Amlodipine 5 mg. The second group received a single-pill fixed-combination of Perindopril 5 mg/Indapamide 1.25 mg/Amlodipine 5 mg. Our research showed significant decreases in systolic (p=0,05) and diastolic (p<0,05) blood pressure in both groups after 12 weeks of treatment. The study also showed a higher percentage of patients who achieved the targeted blood pressure (< 140/90 mmHg) on the single-pill triple combination drug (69.7%) in comparison with the other group (50%). No adverse effects were recorded in both groups.
Our results revealed significant efficacy and tolerability of a single-pill triple-fixed combination Perindopril/Amlodipine/ Indapamide in patients with uncontrolled essential hypertension without comorbidities. |
---|---|
AbstractList | Hypertension is the major risk factor in Serbia and worldwide for the morbidity and mortality from cardiovascular and cerebrovascular diseases. A majority of patients need two or more antihypertensive drugs to adequately control blood pressure.
Our study group consisted of 12 patients with uncontrolled essential hypertension, without comorbidities, divided in two groups and followed for 12 weeks. The first group was treated with a single-pill of fixed-combination Perindopril 5 mg/Indapamide 1.25 mg and an additional tablet of Amlodipine 5 mg. The second group received a single-pill fixed-combination of Perindopril 5 mg/Indapamide 1.25 mg/Amlodipine 5 mg. Our research showed significant decreases in systolic (p=0,05) and diastolic (p<0,05) blood pressure in both groups after 12 weeks of treatment. The study also showed a higher percentage of patients who achieved the targeted blood pressure (< 140/90 mmHg) on the single-pill triple combination drug (69.7%) in comparison with the other group (50%). No adverse effects were recorded in both groups.
Our results revealed significant efficacy and tolerability of a single-pill triple-fixed combination Perindopril/Amlodipine/ Indapamide in patients with uncontrolled essential hypertension without comorbidities. Abstract Hypertension is the major risk factor in Serbia and worldwide for the morbidity and mortality from cardiovascular and cerebrovascular diseases. A majority of patients need two or more antihypertensive drugs to adequately control blood pressure. Our study group consisted of 12 patients with uncontrolled essential hypertension, without comorbidities, divided in two groups and followed for 12 weeks. The first group was treated with a single-pill of fixed-combination Perindopril 5 mg/Indapamide 1.25 mg and an additional tablet of Amlodipine 5 mg. The second group received a single-pill fixed-combination of Perindopril 5 mg/Indapamide 1.25 mg/Amlodipine 5 mg. Our research showed significant decreases in systolic (p=0,05) and diastolic (p<0,05) blood pressure in both groups after 12 weeks of treatment. The study also showed a higher percentage of patients who achieved the targeted blood pressure (< 140/90 mmHg) on the single-pill triple combination drug (69.7%) in comparison with the other group (50%). No adverse effects were recorded in both groups. Our results revealed significant efficacy and tolerability of a single-pill triple-fixed combination Perindopril/Amlodipine/ Indapamide in patients with uncontrolled essential hypertension without comorbidities. |
Author | Balevic, Milijana Miljkovic, Natasa Dragisic, Dalibor Tasic, Danijela Tasic, Nebojsa |
Author_xml | – sequence: 1 givenname: Nebojsa surname: Tasic fullname: Tasic, Nebojsa email: nebtasa@yahoo.com organization: Cardiovascular Institute “Dedinje”, Belgrade, University of Belgrade, Belgrade, Serbia, Milana Tepica 1, 11 000 Belgrade phone: ++38111-3601669 – sequence: 2 givenname: Milijana surname: Balevic fullname: Balevic, Milijana organization: Cardiovascular Institute “Dedinje”, Belgrade, University of Belgrade, Belgrade, Serbia – sequence: 3 givenname: Danijela surname: Tasic fullname: Tasic, Danijela organization: Cardiovascular Institute “Dedinje”, Belgrade, University of Belgrade, Belgrade, Serbia – sequence: 4 givenname: Dalibor surname: Dragisic fullname: Dragisic, Dalibor organization: University Hospital Center “Dr Dragiša Mišovic - Dedinje”, Belgrade, Serbia – sequence: 5 givenname: Natasa surname: Miljkovic fullname: Miljkovic, Natasa organization: Institute for Public Health, Kragujevac, Serbia |
BookMark | eNp1kUFv1DAQhQMqEtvSc6_zB0LsOE42iEu12mVXrcRKLRK3yIknMGlir-ysSvj1OA0SHMCH8Yz13uiz3mV0YazBKLrh7D2XXCa-w8bFKeN5zEJ5Ha1SIWTMCvn1IlrxdcridZ7Lt9G19x0Lp8w4k2L16mbbttSoZgJlNDzaHp2qqadxAtuCgh39QA0bO9Rk1EjWzM9HdGS0PTnqk9uht5pOZDA5GK1OaiCNQAaOQY5m9PBM43fYeh8GUj3spxO6EY0Pyz7AkXo7wsN41hMksG3pSXlj_QiHPzAv846evEG4W0ga6vDfGAsFBQoVxDpgzNrAruBBBQw0YVZh5wB7Wkh-UmeHv1GC4F30plW9x-vf91X0Zbd93Ozj-8-fDpvb-7jha8ZjlTGRo8aylkWtS1aveVOwJk-zPMcia0smMFNFIbkOFbNSZHXetnWWy0YIlOIqSpa9jbPeO2yr8J1BuanirJqjrV6ireZoqzna4Pi4OJ5VP6LT-M2dp9BUnT07E1j_5-QFT7n4BTGJtLA |
CitedBy_id | crossref_primary_10_1161_HYPERTENSIONAHA_120_15781 crossref_primary_10_1080_14737167_2023_2293199 crossref_primary_10_1007_s40256_022_00521_0 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1515/sjecr-2016-0016 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2335-075X |
EndPage | 26 |
ExternalDocumentID | 10_1515_sjecr_2016_0016 10_1515_sjecr_2016_001617121 |
GroupedDBID | --- 0R~ 5VS 9WM ABFKT ACGFS ADBBV ADBLJ AHGSO AIKXB ALMA_UNASSIGNED_HOLDINGS BCNDV EBS EJD GROUPED_DOAJ HZ~ IPNFZ KQ8 O9- OK1 P6G QD8 RIG TR2 AAYXX CITATION |
ID | FETCH-LOGICAL-c1801-a4036ede9b57bd90b81c70c62466e74f903e4a7751da77e4934b6ffb465c33e53 |
ISSN | 1820-8665 |
IngestDate | Fri Aug 23 02:21:57 EDT 2024 Fri Nov 25 00:40:35 EST 2022 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1801-a4036ede9b57bd90b81c70c62466e74f903e4a7751da77e4934b6ffb465c33e53 |
OpenAccessLink | http://www.degruyter.com/doi/10.1515/sjecr-2016-0016 |
PageCount | 6 |
ParticipantIDs | crossref_primary_10_1515_sjecr_2016_0016 walterdegruyter_journals_10_1515_sjecr_2016_001617121 |
PublicationCentury | 2000 |
PublicationDate | 2016-3-1 |
PublicationDateYYYYMMDD | 2016-03-01 |
PublicationDate_xml | – month: 03 year: 2016 text: 2016-3-1 day: 01 |
PublicationDecade | 2010 |
PublicationTitle | Serbian journal of experimental and clinical research |
PublicationYear | 2016 |
Publisher | De Gruyter Open |
Publisher_xml | – name: De Gruyter Open |
SSID | ssj0000941053 |
Score | 2.0027018 |
Snippet | Hypertension is the major risk factor in Serbia and worldwide for the morbidity and mortality from cardiovascular and cerebrovascular diseases. A majority of... Abstract Hypertension is the major risk factor in Serbia and worldwide for the morbidity and mortality from cardiovascular and cerebrovascular diseases. A... |
SourceID | crossref walterdegruyter |
SourceType | Aggregation Database Publisher |
StartPage | 21 |
SubjectTerms | fixed combination hypertension pharmacological therapy |
Title | Efficacy and Tolerability of a Fixed Combination of Perindopril/Amlodipine/Indapamide in Patients with Essential Hypertension: Pilot Study / Efikasnost I Tolerabilnost Fiksne Kombinacije Perindopril/Amlodipin/Indapimida Kod Pacijenata Sa Esencijalnom Hipertenzijom: Pilot Studija |
URI | http://www.degruyter.com/doi/10.1515/sjecr-2016-0016 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9owEPdaKk17qfa97kv3sIdJKCMfjkP2xlYQ7dYJqVTiDTmJmUKBoAS2tX_9zna-gCJ1e7ESx3EuOv98H7o7E_LB555rCeYbwnWZQUOLG5wJ27CYSUMUGJGtXAMXP1j_ip6P3NHB4a9a1NJ6FXwKb-_MK_kfrmIf8lVmyf4DZ8tJsQOvkb_YIoexvRePu7L-gzyvXXq_h8lMpLrq9o3OeuzFf6T_Npmj9VtqhgOZ7xcly1Q6f3ud-SyJ5PHVAm_O0Dxf8nkcqUIiA11xNU9_62YyS0m61_touaYq7l1HhQziWbJS8YgycKDX7E7ia54tkmzVPKuIUve9-DpDpfabpiiMp2IfOQU1MVLD8YWoOVDj8T9485IjOciHeMpx3nmzH2uKbuNpMt8kCYfU1W_cGWWN9Xq9jI0jDlSSX5ErmtdBKv3lQ44rWqEH9-hpVnkyuEzRD3USwgy_uOA7r8hM_qmYlQ9OUy49RvmzWRwkad3_YrEqAC0XGahDGbJqoJaoqs92HNdAZWy0IWe8HTwVQqOmfuj6ATuCzVU1QLIp2hKGpsK07ighviXay4BLaerhFGM1wVhOIIMZ2SE5sj3f9RrkqHP65ft56Z1Eox8Vb5WdUvxeXhcLZ2ltkbGh0h3_VmEekfiZrm9WRViB0taGj8lxbmZBR2PmCTkQi6fk4UUeSPLswcsCOoAshzp0IJkABwUdqEFHdtfWaqsCTquCDcQLKGADEjZQwgbqsPkMaoWCAg20oIIMnMEGZEBDBmqQuZuMVgUXHBxBBRe45FCHC2zApU4KDnhOrnrd4de-kZ-RYoQWKpcGp6iCikj4gesFkW8GbSv0zJDZlDHh0YlvOoJyDzfkCFtBfYcGbDIJKHNDxxGu84I0FslCvCLAIt-PTOrbaCXQSRC2KWdojllU-G2Tm-KEfCzYPF7qUjjjPevqhLhby2CcAzvb94rlWbb1-v6feEMeVWh8SxqrdC3eoX2wCt7ni_kvz8Ufdw |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Sciendo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+Tolerability+of+a+Fixed+Combination+of+Perindopril%2FAmlodipine%2FIndapamide+in+Patients+with+Essential+Hypertension%3A+Pilot+Study+%2F+Efikasnost+I+Tolerabilnost+Fiksne+Kombinacije+Perindopril%2FAmlodipin%2FIndapimida+Kod+Pacijenata+Sa+Esencijalnom+Hipertenzijom%3A+Pilot+Studija&rft.jtitle=Serbian+journal+of+experimental+and+clinical+research&rft.au=Tasic%2C+Nebojsa&rft.au=Balevic%2C+Milijana&rft.au=Tasic%2C+Danijela&rft.au=Dragisic%2C+Dalibor&rft.date=2016-03-01&rft.issn=1820-8665&rft.eissn=2335-075X&rft.volume=17&rft.issue=1&rft.spage=21&rft.epage=26&rft_id=info:doi/10.1515%2Fsjecr-2016-0016&rft.externalDBID=n%2Fa&rft.externalDocID=10_1515_sjecr_2016_0016 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1820-8665&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1820-8665&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1820-8665&client=summon |